Naoki Amada

1.2k total citations
13 papers, 927 citations indexed

About

Naoki Amada is a scholar working on Cellular and Molecular Neuroscience, Pharmacology and Psychiatry and Mental health. According to data from OpenAlex, Naoki Amada has authored 13 papers receiving a total of 927 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cellular and Molecular Neuroscience, 7 papers in Pharmacology and 5 papers in Psychiatry and Mental health. Recurrent topics in Naoki Amada's work include Neuroscience and Neuropharmacology Research (5 papers), Neurotransmitter Receptor Influence on Behavior (4 papers) and Alzheimer's disease research and treatments (3 papers). Naoki Amada is often cited by papers focused on Neuroscience and Neuropharmacology Research (5 papers), Neurotransmitter Receptor Influence on Behavior (4 papers) and Alzheimer's disease research and treatments (3 papers). Naoki Amada collaborates with scholars based in Japan, United Kingdom and United States. Naoki Amada's co-authors include Yuki Yamasaki, Tetsuro Kikuchi, Akihito Watanabe, Haruhiko Sugino, Kenji Maeda, Serena Deiana, Gernot Riedel, Hitomi Akazawa, Jørn Arnt and Robert D. McQuade and has published in prestigious journals such as PLoS ONE, Journal of Pharmacology and Experimental Therapeutics and Psychopharmacology.

In The Last Decade

Naoki Amada

13 papers receiving 905 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Naoki Amada Japan 9 564 366 322 130 118 13 927
Nicolaas Paul L.G. Verhoeff Canada 16 185 0.3× 295 0.8× 219 0.7× 183 1.4× 131 1.1× 36 788
Ani Gasparyan Spain 14 462 0.8× 251 0.7× 81 0.3× 107 0.8× 94 0.8× 31 792
Giorgio Marchese Italy 15 258 0.5× 339 0.9× 137 0.4× 117 0.9× 177 1.5× 43 742
Shan Xie United States 17 474 0.8× 415 1.1× 79 0.2× 122 0.9× 184 1.6× 26 984
Lineke Zuurman Netherlands 14 762 1.4× 471 1.3× 125 0.4× 233 1.8× 60 0.5× 22 1.1k
Leyre Urigüen Spain 18 554 1.0× 572 1.6× 62 0.2× 100 0.8× 195 1.7× 42 996
Robert E. Vann United States 21 670 1.2× 718 2.0× 116 0.4× 144 1.1× 527 4.5× 43 1.4k
Amaya Austrich-Olivares Spain 8 340 0.6× 152 0.4× 73 0.2× 80 0.6× 78 0.7× 10 601
Dorota Żółkowska United States 19 169 0.3× 626 1.7× 300 0.9× 171 1.3× 339 2.9× 57 1.3k
Haruhiko Sugino Japan 8 216 0.4× 195 0.5× 318 1.0× 64 0.5× 109 0.9× 8 710

Countries citing papers authored by Naoki Amada

Since Specialization
Citations

This map shows the geographic impact of Naoki Amada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naoki Amada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naoki Amada more than expected).

Fields of papers citing papers by Naoki Amada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naoki Amada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naoki Amada. The network helps show where Naoki Amada may publish in the future.

Co-authorship network of co-authors of Naoki Amada

This figure shows the co-authorship network connecting the top 25 collaborators of Naoki Amada. A scholar is included among the top collaborators of Naoki Amada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naoki Amada. Naoki Amada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Amada, Naoki, Shinji Sato, Dai Ishikawa, et al.. (2024). Brexpiprazole: A new option in treating agitation in Alzheimer's dementia—Insights from transgenic mouse models. Neuropsychopharmacology Reports. 44(3). 557–568. 2 indexed citations
2.
Amada, Naoki, et al.. (2023). Synergistic anti‐depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice. Neuropsychopharmacology Reports. 43(1). 132–136. 7 indexed citations
3.
4.
Amada, Naoki, Hitomi Akazawa, Yuta Ohgi, et al.. (2019). Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenomena related to D2 and serotonin 5‐HT2A receptors in rats. Neuropsychopharmacology Reports. 39(4). 279–288. 19 indexed citations
5.
Amada, Naoki, Claire Williams, Ian M. Stanford, et al.. (2016). A Low Mortality, High Morbidity Reduced Intensity Status Epilepticus (RISE) Model of Epilepsy and Epileptogenesis in the Rat. PLoS ONE. 11(2). e0147265–e0147265. 20 indexed citations
6.
Deiana, Serena, Akihito Watanabe, Yuki Yamasaki, et al.. (2015). MK-801-induced deficits in social recognition in rats. Behavioural Pharmacology. 26(8). 748–765. 34 indexed citations
7.
Sugino, Haruhiko, Akihito Watanabe, Naoki Amada, et al.. (2015). Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success. Clinical Therapeutics. 37(8). 1632–1642. 32 indexed citations
8.
Maeda, Kenji, Haruhiko Sugino, Hitomi Akazawa, et al.. (2014). Brexpiprazole II: Antipsychotic-Like and Procognitive Effects of a Novel Serotonin-Dopamine Activity Modulator. Journal of Pharmacology and Experimental Therapeutics. 350(3). 605–614. 109 indexed citations
9.
Maeda, Kenji, Haruhiko Sugino, Hitomi Akazawa, et al.. (2014). Brexpiprazole I: In Vitro and In Vivo Characterization of a Novel Serotonin-Dopamine Activity Modulator. Journal of Pharmacology and Experimental Therapeutics. 350(3). 589–604. 278 indexed citations
10.
Amada, Naoki, Yuki Yamasaki, Claire Williams, & Benjamin J. Whalley. (2013). Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression. PeerJ. 1. e214–e214. 68 indexed citations
11.
12.
Amada, Naoki, et al.. (2005). Reduction of NR1 and phosphorylated Ca2+/calmodulin-dependent protein kinase II levels in Alzheimer's disease. Neuroreport. 16(16). 1809–1813. 44 indexed citations
13.
Amada, Naoki. (2003). A Novel Rat Orthologue and Homologue for the Drosophila crooked neck Gene in Neural Stem Cells and Their Immediate Descendants. The Journal of Biochemistry. 133(5). 615–623. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicolaas Paul L.G. Verhoeff Breakdown of academic impact, for papers by Ani Gasparyan Breakdown of academic impact, for papers by Giorgio Marchese Breakdown of academic impact, for papers by Shan Xie Breakdown of academic impact, for papers by Lineke Zuurman Breakdown of academic impact, for papers by Leyre Urigüen Breakdown of academic impact, for papers by Robert E. Vann Breakdown of academic impact, for papers by Amaya Austrich-Olivares Breakdown of academic impact, for papers by Dorota Żółkowska Breakdown of academic impact, for papers by Haruhiko Sugino
Rankless by CCL
2026